Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Venous stenosis** refers to the narrowing (stenosis) or blockage (obstruction) of a vein. This is not a single molecular target but rather an anatomical and pathological condition affecting various veins throughout the body. Commonly affected sites include central thoracic veins such as the subclavian, brachiocephalic, and superior vena cava—especially in patients with prior central venous catheterization for hemodialysis or cardiac devices[2][6][7]. In some contexts, "venous stenosis" may refer specifically to **pulmonary vein stenosis**, which affects blood return from the lungs to the heart and can lead to severe complications like pulmonary hypertension and heart failure if untreated[1][3].\n\nThe pathophysiology involves either thrombotic processes—such as chronic sequelae after deep vein thrombosis—or non-thrombotic causes like external compression by tumors or fibrotic tissue. The resulting impaired blood flow leads to increased upstream pressure ("venous hypertension"), swelling, pain, skin changes, ulceration, and sometimes life-threatening complications depending on location[4][5].\n\nDiagnosis relies on imaging modalities such as duplex ultrasonography for initial assessment; CT/MR venography; but gold standard confirmation is via conventional angiography[7]. Treatment strategies are primarily interventional—including percutaneous transluminal angioplasty with/without stent placement—and surgical reconstruction in select cases. Medical management includes anticoagulation for thrombotic causes and supportive care for symptoms.\n\n**Venous stenosis/obstruction is not a molecular drug target** like a receptor or enzyme but rather an anatomical lesion that may be addressed by drugs only indirectly through management of underlying causes such as thromboses.\n\n---\n\n**Key points:** \n• "Venous stenosis/obstruction" describes an anatomical/pathological state—not a discrete molecule/receptor/enzyme/transporter.\n• It is not considered a canonical therapeutic target at the molecular level.\n• The term encompasses several clinical entities depending on location—central venous system vs. pulmonary veins—with different implications.\n• Management focuses on restoring patency mechanically/interventionally rather than targeting specific molecules within the vessel wall.\n\nIf you need information about specific molecular targets involved in processes leading to venous narrowing—such as those mediating fibrosis/thrombogenesis/myofibroblast proliferation—please specify further.
Reduction of thrombosis risk by anticoagulation\nRelief of vascular congestion and hypertension through endovascular intervention or surgery
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Venous stenosis.